This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

8 Mar 2013

OncoMed begins Phase 1 clinical trial of stem cell drug

OMP-52M51 is a therapeutic that targets cancer stem cells.

OncoMed Pharmaceuticals is carrying out a Phase 1 clinical trial into an anti-cancer stem cell treatment.

OMP-52M51 will be tested in patients with advanced refractory solid tumours. Dosing has already begun.
The company specialises in therapeutics that target cancer stem cells and tumour-initiating cells. OMP-52M51 is its fifth product to enter clinical testing.

Patients in the open-label dose escalation and expansion study will be monitored for safety and initial efficacy of the drug.

Dr Amita Patnaik, who treated the first patient in the trial, said an accompanying predictive diagnostic test made the study "cutting edge".

Earlier this week, Silence Therapeutics was given the go ahead for a Phase 1b/2a combination clinical trial for Atu027 compound in the treatment of pancreatic cancer.


Related News